Combining mTor Inhibitors With Rapamycin-resistant T Cells: A Two-pronged Approach to Tumor Elimination
Open Access
- 1 December 2011
- journal article
- Published by Elsevier BV in Molecular Therapy
- Vol. 19 (12), 2239-2248
- https://doi.org/10.1038/mt.2011.179
Abstract
No abstract availableKeywords
This publication has 38 references indexed in Scilit:
- T Cells Expressing Constitutively Active Akt Resist Multiple Tumor-associated Inhibitory MechanismsMolecular Therapy, 2010
- Fifteen Years of Gene Therapy Based on Chimeric Antigen Receptors: “Are We Nearly There Yet?”Human Gene Therapy, 2009
- Immunoregulatory functions of mTOR inhibitionNature Reviews Immunology, 2009
- Genetic Manipulation of Tumor-specific Cytotoxic T Lymphocytes to Restore Responsiveness to IL-7Molecular Therapy, 2009
- Adoptive cell therapy for the treatment of patients with metastatic melanomaCurrent Opinion in Immunology, 2009
- Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastomaNature Medicine, 2008
- The tumor microenvironment and its role in promoting tumor growthOncogene, 2008
- mTORC1 promotes survival through translational control of Mcl-1Proceedings of the National Academy of Sciences of the United States of America, 2008
- Role of mTOR in anticancer drug resistance: Perspectives for improved drug treatmentDrug Resistance Updates, 2008
- PiggyBac Transposon-mediated Gene Transfer in Human CellsMolecular Therapy, 2007